Protein Sciences Corp Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Meriden CT United States (1983)
Status: Acquired by Sanofi-Aventis (2017)

Organization Overview

First Clinical Trial
1999
NCT00000745
First Marketed Drug
2013
inactivated influenza vaccine
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

MicroGeneSys Inc | MicroGeneSys Inc (nka Protein Sciences Corporation) | Protein Sciences Corporation

Active Ingredients

Marketed Drugs (1)

inactivated influenza vaccine (2013)

Drugs in Phase 3 Trials (4)

fluarix (1 trial)

inactivated influenza vaccine (3 trials)

influenza vaccine, recombinant hemagglutinin (7 trials)

tivantinib (1 trial)

Drugs in Phase 2 Trials (1)

panblok (3 trials)

Drugs in Phase 1 Trials (1)

gp160 vaccine (6 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acquired Immunodeficiency Syndrome (Phase 1)

Communicable Diseases (Phase 1)

HIV Infections (Phase 1)

HIV Seropositivity (Phase 1)

Hypersensitivity (Phase 1)

Hypersensitivity, Delayed (Phase 1)

Infections (Phase 1)

Influenza, Human (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 18
  • # of Trial APIs: 6